COVID-19. TO MANUFACTURE AND EVALUATE THE SAFETY, EFFICACY AND TOLERABILITY OF GALIDESIVIR A BROAD SPECTRUM, ANTIVIRAL THERAPEUTIC.

DEFINITIVE CONTRACT won by BIOCRYST PHARMACEUTICALS INC · work in DURHAM, NC
$6,326,480
RecipientBIOCRYST PHARMACEUTICALS INC UEI MGXADJ6SCLJ5
Award ID75N93020C00055
Award amount$6,326,480
Award typeDEFINITIVE CONTRACT
Awarding agencyDepartment of Health and Human Services — National Institutes of Health
NAICS541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
PSCAJ12
Start dateSep 1, 2020
End dateSep 30, 2022
Place of performanceDURHAM, NC
Record updatedMay 27, 2022

View the official award record

More awards won by BIOCRYST PHARMACEUTICALS INC

BPA FOR ORLADEYO AND RAPIVAB
Department of Veterans Affairs · $93,000,000 · Jun 3, 2026
IGF::OT::IGF - DEVELOPMENT OF MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES, BASE, OPTION 1 AND OPTION 2 AWARD, 09/16/2013 - 09/15/2017
Department of Health and Human Services · $47,755,723 · Sep 16, 2013
PERAMIVIR, RAPIVAB FLU TREATMENT
Department of Health and Human Services · $34,660,000 · Sep 1, 2018
PERAMIVIR (RAPIVAB 200MG/20ML (10MG/ML INJ SOLN))
Department of Health and Human Services · $13,877,674 · Sep 30, 2024
BULK ORLADEYO PHARMACEUTICAL
Department of Veterans Affairs · $394,853 · Mar 12, 2025

Our catalog shows awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.

Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. Free for 14 days, then $49.99/month.

Search open bids